Journal Mobile Options
Table of Contents
Vol. 27, No. 5, 2009
Issue release date: June 2009

Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε44 Genotype

Blom E.S. · Giedraitis V. · Zetterberg H. · Fukumoto H. · Blennow K. · Hyman B.T. · Irizarry M.C. · Wahlund L.-O. · Lannfelt L. · Ingelsson M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Increased cerebrospinal fluid (CSF) tau, decreased CSF amyloid-β42 (Aβ42) and the apolipoprotein E gene (APOE) ε4 allele predict progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). Here, we investigated these markers to assess their predictive value and influence on the rate of disease progression. Methods: Using ELISA, we measured the CSF biomarkers in 47 AD patients, 58 patients with MCI and 35 healthy control subjects. Twenty-eight MCI patients revisited the clinic and half of them progressed to AD during a period of 3–12 years. Results: The expected changes in CSF total (T)-tau, phosphorylated (P)-tau and Aβ42 levels were found in AD, confirming the diagnostic value of these biomarkers. We were also able to corroborate an increased risk for progression from MCI to AD with elevated CSF T-tau and P-tau and with the presence of the APOE ε4/ε4 genotype, but not with decreased Aβ42. Finally, for the first time we demonstrated that MCI subjects with high CSF T-tau or P-tau and APOE ε4 homozygosity progressed faster from MCI to AD. Conclusions: CSF T-tau and P-tau as well as the APOE ε4/ε4 genotype are robust predictors of AD and are also associated with a more rapid progression from MCI to AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Blennow K: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 2004;1:213–225.
  2. Hansson O, Zetterberg H, Buchhave P, et al: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.
  3. Prince JA, Zetterberg H, Andreasen N, et al: APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 2004;62:2116–2118.
  4. Galasko D, Chang L, Motter R, et al: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937–945.
  5. Tapiola T, Pirttila T, Mehta PD, et al: Relationship between apoE genotype and CSF beta-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease. Neurobiol Aging 2000;21:735–740.
  6. Sunderland T, Mirza N, Putnam KT, et al: Cerebrospinal fluid beta-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004;56:670–676.
  7. Herukka SK, Helisalmi S, Hallikainen M, et al: CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging 2007;28:507–514.
  8. McKhann G, Drachman D, Folstein M: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  9. Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  10. Ingelsson M, Shin Y, Irizarry MC, et al: Genotyping of apolipoprotein E: comparative evaluation of different protocols. Curr Protoc Hum Genet 2003;Chapter 9:Unit 9.14.
  11. Blennow K, Wallin A, Ågren H, et al: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer’s disease? Mol Chem Neuropathol 1995;26:231–245.
  12. Vanmechelen E, Vanderstichele H, Davidsson P, et al: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49–52.
  13. Ingelsson M, Fukumoto H, Newell K, et al: Early Abeta accumulation and progressive synaptic loss, gliosis and tangle formation in AD brain. Neurology 2004;62:925–931.
  14. Rosner B: Fundamentals of Biostatistics, ed 6. Florence KY, Cengage Learning Inc., 2006.
  15. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, et al: Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 2003;60:1202–1206.
  16. Corder EH, Saunders AM, Strittmatter WJ, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  17. Sando SB, Melquist S, Cannon A, et al: APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer’s disease; a case control study from central Norway. BMC Neurol 2008;8:9.
  18. Hansson O, Zetterberg H, Buchhave P, et al: Prediction of Alzheimer’s disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:316–320.
  19. Klunk WE, Engler H, Nordberg A, et al: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.
  20. Klunk WE, Price JC, Mathis CA, et al: Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174– 6184.
  21. Forsberg A, Engler H, Almkvist O, et al: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456–1465.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50